350 FIFTH AVENUE, NEW YORK, NY
Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
VP of Finance John Militello Resigns; Joseph Manhede Appointed Principal Acco...
Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Stockholders Elect Seven Directors at Rocket Pharmaceuticals Annual Meeting
Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Announces $180 Million Sale of Priority Review Voucher
Annual Report to Security Holders
Q2
FY 2024
Q3
Q1
Registration Statement for Securities to be Offered to Employees
SC TO-I
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement